HRT in Hypopituitarism – Women	

In women, a typical regimen involves the administration of ethinyloestradiol (30µg daily) or oestradiol valerate (2mg daily) for three weeks out of four and, for ten days in each calendar month, medroxyprogesterone (5mg daily), after which time a withdrawal bleed occurs. Libido, vaginal dryness and breast atrophy are remedied. If hypopituitarism develops at a young age, osteoporosis will be prevented by adequate sex steroid treatment. If ovulation is required, treatment may be given either with human menopausal gonadotrophin (such as menotrophin) or with GnRH delivered intermittently with a pump.